These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21945203)

  • 1. Design and synthesis of biotinylated DHMEQ for direct identification of its target NF-κB components.
    Saitoh T; Takeiri M; Gotoh Y; Ishikawa Y; Umezawa K; Nishiyama S
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6293-6. PubMed ID: 21945203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible role of peritoneal NF-κB in peripheral inflammation and cancer: lessons from the inhibitor DHMEQ.
    Umezawa K
    Biomed Pharmacother; 2011 Jul; 65(4):252-9. PubMed ID: 21723080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
    Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
    Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.
    Katsman A; Umezawa K; Bonavida B
    Drug Resist Updat; 2007; 10(1-2):1-12. PubMed ID: 17306602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Starenki DV; Namba H; Saenko VA; Ohtsuru A; Maeda S; Umezawa K; Yamashita S
    Clin Cancer Res; 2004 Oct; 10(20):6821-9. PubMed ID: 15501958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.
    Kimura N; Miyakawa Y; Kohmura K; Umezawa K; Ikeda Y; Kizaki M
    Leuk Res; 2007 Nov; 31(11):1529-35. PubMed ID: 17466373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient synthesis of (+/-)-parasitenone, a novel inhibitor of NF-kappaB.
    Saitoh T; Suzuki E; Takasugi A; Obata R; Ishikawa Y; Umezawa K; Nishiyama S
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5383-6. PubMed ID: 19666224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
    Lampiasi N; Azzolina A; D'Alessandro N; Umezawa K; McCubrey JA; Montalto G; Cervello M
    Mol Pharmacol; 2009 Aug; 76(2):290-300. PubMed ID: 19461054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
    Kuroda K; Horiguchi Y; Nakashima J; Kikuchi E; Kanao K; Miyajima A; Ohigashi T; Umezawa K; Murai M
    Clin Cancer Res; 2005 Aug; 11(15):5590-4. PubMed ID: 16061877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
    Ruan HY; Masuda M; Ito A; Umezawa K; Nakashima T; Yasumatsu R; Kuratomi Y; Yamamoto T; Weinstein IB; Komune S
    Head Neck; 2006 Feb; 28(2):158-65. PubMed ID: 16355386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of histidine decarboxylase in macrophages inhibited by the novel NF-kappaB inhibitor (-)-DHMEQ.
    Suzuki E; Ninomiya Y; Umezawa K
    Biochem Biophys Res Commun; 2009 Feb; 379(2):379-83. PubMed ID: 19103154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Suzuki E; Umezawa K
    Biomed Pharmacother; 2006 Nov; 60(9):578-86. PubMed ID: 16978829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
    Nishimura D; Ishikawa H; Matsumoto K; Shibata H; Motoyoshi Y; Fukuta M; Kawashimo H; Goto T; Taura N; Ichikawa T; Hamasaki K; Nakao K; Umezawa K; Eguchi K
    Int J Oncol; 2006 Sep; 29(3):713-9. PubMed ID: 16865289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ).
    Horiuchi K; Morioka H; Nishimoto K; Suzuki Y; Susa M; Nakayama R; Kawai A; Sonobe H; Takaishi H; Ozaki T; Yabe H; Umezawa K; Toyama Y
    Cancer Lett; 2008 Dec; 272(2):336-44. PubMed ID: 18760530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation of radioactively labeled dehydroxymethyl-epoxyquinomicin, an NF-kappa B function inhibitor.
    Chaicharoenpong C; Kato K; Umezawa K
    Drugs Exp Clin Res; 2003; 29(1):1-3. PubMed ID: 12866358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antineoplastic Effects of NF-κB Inhibition by DHMEQ (Dehydroxymethylepoxyquinomicin) Alone and in Co-treatment with Radio-and Chemotherapy in Medulloblastoma Cell Lines.
    Ramos PMM; Pezuk JA; Castro-Gamero AM; Oliveira HF; Scrideli CA; Umezawa K; Tone LG
    Anticancer Agents Med Chem; 2018; 18(4):541-549. PubMed ID: 29141555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts.
    Makino S; Mitsutake N; Nakashima M; Saenko VA; Ohtsuru A; Umezawa K; Tanaka K; Hirano A; Yamashita S
    J Dermatol Sci; 2008 Sep; 51(3):171-80. PubMed ID: 18406579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues.
    Yamamoto M; Horie R; Takeiri M; Kozawa I; Umezawa K
    J Med Chem; 2008 Sep; 51(18):5780-8. PubMed ID: 18729348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF-kappaB inhibitor.
    Takatsuna H; Morita S; Nagatsu T; Sawada M; Umezawa K
    Biomed Pharmacother; 2005 Jul; 59(6):318-22. PubMed ID: 15932789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.